Actively Managed ETF following Laffer Tengler’s Equity Income Strategy SCOTTSDALE, Ariz. and NASHVILLE, Tenn., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Laffer Tengler Investments, a boutique investment management firm for high-net worth individuals, institutional clients and platform advisors, today announced the two-year anniversary of the LAFFER | TENGLER Equity Income ETF (TGLR) launched on August 8, 2023. TGLR ranked in the 1st percentile of funds in Morningstar’s Large Cap Value Universe (out of 1,129 Funds) based on Total Return for the 1 year time period ending July 31, 2025. For information on the Fund’s performance and rankings, please visit Morningstar: https://www.morningstar.com/etfs/bats/tglr/performance TGLR is actively managed and seeks to achieve its investment objective by investing in high quality, large-cap stocks that Laffer Tengler Investments believes have strong earnings and dividend growth potential as well as an above market dividend yield. The strategy utilizes two valuation metrics that Laffer Tengler Investments believes are consistent indicators of value: Relative Dividend Yield (RDY) and Relative Price-to Sales Ratio (RPSR).  For information on the Fund’s performance, please visit the Fund’s website: LAFFER | TENGLER Equity Income ETF (TGLR). Source- TGLRetf.com The strategy behind TGLR typically holds 25-35 positions, produces a dividend yield and is considered low turnover. TGLR follows the Laffer Tengler Equity Income Strategy, run by Nancy Tengler, a media personality, which, previously, had only been available in separately managed accounts to wealth management and institutional investors. “We’re pleased that the methodology for this strategy, a unique and disciplined way to look at companies that pay and grow their dividends, has paid off over the past two years,” said CEO and CIO at Laffer Tengler Investments, Nancy Tengler. “We look forward to continue bringing this strategy, which we began using in the mid-1980s and, over time, has proven to be extremely reliable, to investors, and seeing how TGLR continues to grow,” Tengler added. Performance Disclosure The performance data quoted represents past performance. Past performance does not guarantee future results. The investment return and principal value of an investment will fluctuate so that an investor’s shares, when sold or redeemed, may be worth more or less than their original cost and current performance may be lower or higher than the performance quoted. Returns less than one year are not annualized. Short term performance, in particular, is not a good indication of the fund’s future performance, and an investment should not be made solely based on returns. The Fund’s inception date is August 8, 2023. The total expense ratio is 0.95%. Morningstar classifies funds into categories based on similar investment objective and strategy. Morningstar percentile rankings are based on a fund's total return compared to its Morningstar Category of exchange-traded and open-end mutual funds. The highest percentile rank is 1 and the lowest percentile rank is 100. Rankings are relative to a peer group and do not necessarily mean the fund had high or positive total returns. Past performance does not guarantee future results. Investors should carefully consider the investment objectives, risks, charges and expenses of the ETF. This and other important information about the Fund are contained in the prospectus, which can be obtained on the website, https://www.tglretf.com or by calling 833-759-6110. The prospectus should be read carefully before investing. Distributor: Foreside Fund Services, LLC, member FINRA. Foreside Fund Services, LLC is not affiliated with the Laffer Tengler Equity Income ETF. For information on the Fund’s performance and rankings, please visit Morningstar: https://www.morningstar.com/etfs/bats/tglr/performance Media Contact Deborah Kostroun, Zito Partnersdeborah@zitopartners.com+1 (201) 403-8185 A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/c2118b40-7beb-405c-9691-9ca97506c090 The post LAFFER | TENGLER Equity Income ETF (TGLR) Celebrates Two-Year Anniversary appeared first on ForexTV.

Delray Beach, FL, Aug. 11, 2025 (GLOBE NEWSWIRE) -- The global physiotherapy equipment market is projected to expand from USD 6.70 billion in 2024 to USD 9.45 billion by 2029, registering a CAGR of 7.1%. What’s driving this growth? A convergence of critical healthcare shifts — from the rising prevalence of chronic and lifestyle-related conditions, to the aging global population, to accelerating adoption of home-based rehabilitation technologies. While market momentum is strong, C-suite leaders should also note challenges such as stringent regulatory requirements, high upfront investment costs, and volatile reimbursement policies, which may affect go-to-market strategies. Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=65250228 What’s Behind the Market’s Momentum?The demand surge is anchored in musculoskeletal rehabilitation needs, post-surgical recovery, sports injury management, and preventive care. Technological innovations, such as miniaturized and portable devices, are reshaping care delivery models, making treatment more accessible and patient-centric. As healthcare systems pivot towards cost efficiency, home healthcare and personalized rehabilitation are gaining prominence, offering new revenue streams for providers and equipment manufacturers alike. Where Are the Opportunities by Segment? By Product – The equipment segment dominates, driven by the widespread use of electrotherapy, ultrasound therapy, cryotherapy, and other modalities in both clinical and home settings. By Application – Musculoskeletal conditions remain the top revenue driver, fueled by aging demographics and the prevalence of arthritis, osteoporosis, cardiovascular disease, and diabetes. By End User – Physiotherapy and rehabilitation centers lead adoption, positioning themselves as innovation hubs for new technology deployment and specialized care delivery. Which Regions Lead – and Why?North America holds the largest market share, underpinned by its advanced healthcare infrastructure, high healthcare spending, and readiness to integrate cutting-edge physiotherapy technologies. Favorable reimbursement structures and a growing preventive care culture further strengthen regional leadership. Who’s Driving Innovation?Key market players are advancing capabilities through R&D, strategic acquisitions, and portfolio diversification: Enovis Corp. (US) – Pioneers in functional knee bracing (DonJoy) and medical laser therapy (LiteCure), serving over 1.2 million treatments monthly across 29 countries. Zimmer Medizinsysteme GmbH (Germany) – European leader in cryotherapy and electrotherapy, expanding global reach through acquisitions like FREI Capital and Enraf Nonius. Zynex Inc. (US) – Specializes in FDA-approved portable electrotherapy devices, capitalizing on recurring revenue from consumables and expanding product offerings. Why This Matters for Decision-Makers NowThe physiotherapy equipment market is no longer a niche rehabilitative segment — it is becoming a strategic growth pillar for healthcare providers, medtech innovators, and investors. Healthcare Providers can tap into recurring revenue models through consumables and service packages. Manufacturers have opportunities in personalization, AI-assisted rehab devices, and emerging markets. Investors should track regulatory trends and tele-rehabilitation adoption for high-growth potential. For more information, Inquire Now! Discover Connected Healthcare Market Opportunities:Dental Equipment MarketSterilization Equipment MarketEndoscopy Equipment MarketSports Medicine MarketPain Management Devices Market Get access to the latest updates on Physiotherapy Equipment Companies and Physiotherapy Equipment Market Share CONTACT: About MarketsandMarkets™ MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook. Contact: Mr. Rohan Salgarkar MarketsandMarkets™ INC. 1615 South Congress Ave. Suite 103, Delray Beach, FL 33445, USA: +1-888-600-6441 Email: sales@marketsandmarkets.com Visit Our Website: www.marketsandmarkets.com The post Physiotherapy Equipment Market to Surge to USD 9.45 Billion by 2029 | MarketsandMarkets™. appeared first on ForexTV.

NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Fluent, Inc. (NASDAQ: FLNT), a leader in commerce media, today announced that Don Patrick, Chief Executive Officer, will attend the 45th Annual Canaccord Genuity Growth Conference on Wednesday, August 13, 2025, at the InterContinental Boston. Mr. Patrick will participate in a fireside chat at 12:00pm ET on Wednesday, August 13, and is available for one-on-one meetings throughout the day. A live webcast of the fireside chat will be available at the following link:https://wsw.com/webcast/canaccord108/flnt/2525900 A replay of the fireside chat will also be available at the link following the conclusion of the live event. About Fluent, Inc.Fluent, Inc. (NASDAQ: FLNT) is a commerce media solutions provider connecting top-tier brands with highly engaged consumers. Leveraging exclusive ad inventory, robust first-party data, and proprietary machine learning, Fluent unlocks additional revenue streams for partners and empowers advertisers to acquire their most valuable customers at scale. Founded in 2010, Fluent uses its deep expertise in performance marketing to drive monetization and increase engagement at key touchpoints across the customer journey. For more insights, visit https://www.fluentco.com. ContactInvestor RelationsFluent, Inc.InvestorRelations@fluentco.com The post Fluent, Inc. to Attend 45th Annual Canaccord Genuity Growth Conference appeared first on ForexTV.

HONG KONG, Aug. 11, 2025 (GLOBE NEWSWIRE) -- via IBN – SOLOWIN HOLDINGS (NASDAQ: SWIN) (“Solowin” or the “Company”), a leading financial services firm providing comprehensive solutions across traditional and digital assets, today announced that its wholly-owned subsidiary Solomon JFZ (Asia) Holdings Limited (“Solomon”) has processed a total transaction volume of $100 million since launching its operational coin-in and coin-out services. This milestone underscores the strategic significance of Solomon’s recent licensing achievements from the Hong Kong Securities and Futures Commission (SFC) as the city’s virtual asset market enters a phase of accelerated growth. This achievement follows Solowin’s strategic expansion since 2023 to bridge traditional finance and decentralized finance. The upgraded licensing enables the Company to provide regulated coin-in/coin-out functionality, securely connecting fiat and digital asset ecosystems while adhering to Hong Kong’s stringent compliance standards. Solomon’s one-stop wealth management platform is designed to fully comply with the SFC’s rigorous requirements, including: Asset Custody Standards: Adopting secure, multi-layer custody technology, with a significant majority of client assets held in cold storage, to meet the stringent offline asset requirements mandated by Hong Kong regulators; AML and KYC Compliance: Integrating robust regulatory technology (RegTech) solutions for customer due diligence, transaction screening, and Travel Rule adherence; Market Integrity and Operational Oversight: Ensuring segregation of client funds, conflict-of-interest mitigation, and real-time monitoring tools to uphold and promote evolving market integrity. Solowin is strategically positioned within Hong Kong’s rapidly developing regulatory framework for virtual assets. The company intends to capitalize on its position through several key initiatives: Leveraging first-mover advantage in SFC-licensed services; Deepening partnerships with global stablecoin issuers to enhance real-time, cross-border payment solutions and support the growing tokenized asset ecosystem; Exploring the launch of institutional staking products and other regulated, on-chain yield-generating strategies to meet institutional demand for compliant digital asset returns. Peter Lok, CEO of Solowin commented: “Hong Kong is rapidly emerging as Asia’s hub for compliant virtual assets, and Solomon’s regulatory advantages position us to provide institutional investors with secure, efficient digital asset on-ramps. Moving forward, we will continue expanding into real-world asset (RWA) tokenization and institutional-grade decentralized finance (DeFi) solutions to drive convergence between traditional finance and blockchain technology.” About SOLOWIN HOLDINGS SOLOWIN HOLDINGS (NASDAQ: SWIN) is a leading financial services firm providing comprehensive solutions across traditional and digital assets. Founded in 2016, it has delivered a unique, full-spectrum ecosystem that seamlessly bridges traditional and decentralized finance, tailored to the evolving demands of the next-generation global economy. Leveraging its Hong Kong Securities and Futures Commission (SFC) licensed subsidiaries with full digital asset capabilities, the Company operates a robust Web3 Infrastructure Division. Through its self-developed, vertically integrated, enterprise-grade platform, Solowin delivers compliance traditional finance (TradFi), real-world asset (RWA) tokenization, and global digital payment solutions—solidifying its role as a key player in reshaping global finance through a seamless Web3-to-TradFi ecosystem. For more information, visit the Company’s website at https://solowin.io or investor relationship website at https://ir.solowin.io. Forward-Looking Statements Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company's current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. We have attempted to identify these forward-looking statements by words or phrases such as "may," "will," "expect," "anticipate," "aim," "estimate," "intend," "plan," "believe," "is/are likely to," "potential," "continue" or other similar expressions. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations that arise after the date hereof, except as may be required by law. These statements are subject to uncertainties and risks including, but not limited to, the uncertainties related to market conditions and other factors discussed in the Company's filings with the U.S. Securities and Exchange Commission (the “SEC”) including the "Risk Factors" section of the Company's most recent Annual Report on Form 20-F as well as in its other reports filed or furnished from time to time with the SEC. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company's filings with the SEC, which are available for review at www.sec.gov. For investor and media inquiries please contact: SOLOWIN HOLDINGS Investor Relations Department Email: ir@solomonwin.com.hk Ascent Investor Relations LLC Tina Xiao Phone: +1-646-932-7242 Email: investors@ascent-ir.com Corporate Communications IBN Austin, Texas www.InvestorBrandNetwork.com Phone: +1-512-354-7000 Email: Editor@InvestorBrandNetwork.com The post SOLOWIN Expands Virtual Asset Services with Key License and Reports Significant Transactional Volume Growth appeared first on ForexTV.

Geneva, Switzerland, Aug. 11, 2025 (GLOBE NEWSWIRE) -- With a total $30 Million investment capacity, SEALSQ shares strategic updates on ColibriTD and IC’Alps SEALSQ Corp (NASDAQ: LAES) ("SEALSQ" or "Company"), a leading provider of Semiconductors, PKI, and Post-Quantum technology hardware and software products, today unveiled the progress of its SEALQuantum.com Lab, a next-generation research and development hub focused on the convergence of quantum computing, and cybersecurity now Expanding into artificial intelligence (AI). With a total of $30 Million investment capacity, the Lab has already invested in quantum technology startups like ColibriTD and made the acquisition of semiconductor design service specialist IC’ALPS to develop tailor made advanced solutions for semiconductor manufacturing and post-quantum security. Now adding AI as a key component of the Lab’s roadmap, SEALSQ is positioning itself at the forefront of the quantum revolution, addressing today’s industry challenges while preparing for a future Quantum-AI convergence. The SEALQuantum.com Lab is dedicated to developing quantum technologies that enhance semiconductor design and cybersecurity, with a vision to integrate AI in the future to optimize quantum systems and algorithms. By investing in and collaborating with deep tech startups, SEALSQ is driving practical solutions for advanced chip manufacturing and quantum-resistant security, laying the groundwork for hybrid quantum-classical systems that could transform computational efficiency and data protection. “Quantum, cybersecurity, and AI are converging fast, and SEALQuantum.com is where that convergence becomes real,” said Carlos Moreira, CEO and founder of SEALSQ. “By combining our semiconductor and PQC expertise with partners like quantum specialist ColibriTD and semiconductor specialist Xdigit, we demonstrate how quantum technology can dramatically improve the efficiency of semiconductor design. Together, we are tackling critical semiconductor simulation challenges that span performance, efficiency, and resilience in next-generation technologies. Our investment strategy is not just about funding innovation, but about accelerating the deployment of secure, intelligent systems that will define the future of digital infrastructure. With our customers and partners, we are building a quantum-safe future." Quantum technologies for semiconductor design and optimization An illustration following SEALSQ’s investment in ColibriTD is the joint development project, announced in June 2025, to address enhanced semiconductor modeling & simulation and IR Drop challenges in chip manufacturing at sub-7nm nodes. IR Drop — voltage loss due to resistance in power distribution — poses a significant hurdle in producing reliable, high-performance chips for applications like AI servers and smartphones. The collaboration leverages quantum-powered mathematical modeling to simulate and optimize power distribution, delivering faster and more precise results than classical methods. This quantum-enabled approach improves wafer yields, reduces manufacturing defects, and enhances the efficiency and sustainability of advanced semiconductors, addressing critical industry needs. (Further details are provided in this Podcast: https://t.co/pLmAXqm7Dt) Post-quantum cybersecurity for edge devices, AI and infrastructure AI models today, particularly large ones like foundation models, require massive computational power and are vulnerable to cyber threats. SEALQuantum is developing quantum-resistant cryptographic technologies that could protect AI models, training data, and inference processes from current and future attacks including those from quantum computers by embedding post-quantum cryptography into secure chips. Preparing for the quantum-AI convergence of tomorrow. SEALQuantum.com continues to advance its initiatives, with ongoing projects in quantum-enhanced semiconductor optimization and post-quantum cybersecurity. These efforts solidify SEALSQ’s leadership in the global transition to quantum-ready technologies, delivering solutions for today’s challenges while preparing for the quantum-AI convergence of tomorrow. About SEALSQ:SEALSQ is a leading innovator in Post-Quantum Technology hardware and software solutions. Our technology seamlessly integrates Semiconductors, PKI (Public Key Infrastructure), and Provisioning Services, with a strategic emphasis on developing state-of-the-art Quantum Resistant Cryptography and Semiconductors designed to address the urgent security challenges posed by quantum computing. As quantum computers advance, traditional cryptographic methods like RSA and Elliptic Curve Cryptography (ECC) are increasingly vulnerable. SEALSQ is pioneering the development of Post-Quantum Semiconductors that provide robust, future-proof protection for sensitive data across a wide range of applications, including Multi-Factor Authentication tokens, Smart Energy, Medical and Healthcare Systems, Defense, IT Network Infrastructure, Automotive, and Industrial Automation and Control Systems. By embedding Post-Quantum Cryptography into our semiconductor solutions, SEALSQ ensures that organizations stay protected against quantum threats. Our products are engineered to safeguard critical systems, enhancing resilience and security across diverse industries. For more information on our Post-Quantum Semiconductors and security solutions, please visit www.sealsq.com. Forward-Looking StatementsThis communication expressly or implicitly contains certain forward-looking statements concerning SEALSQ Corp and its businesses. Forward-looking statements include statements regarding our business strategy, financial performance, results of operations, market data, events or developments that we expect or anticipates will occur in the future, as well as any other statements which are not historical facts. Although we believe that the expectations reflected in such forward-looking statements are reasonable, no assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates which are inherently subject to significant uncertainties and contingencies, many of which are beyond our control. Actual results may differ materially from those expressed or implied by such forward-looking statements. Important factors that, in our view, could cause actual results to differ materially from those discussed in the forward-looking statements include SEALSQ's ability to continue beneficial transactions with material parties, including a limited number of significant customers; market demand and semiconductor industry conditions; and the risks discussed in SEALSQ's filings with the SEC. Risks and uncertainties are further described in reports filed by SEALSQ with the SEC. SEALSQ Corp is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. SEALSQ Corp.Carlos MoreiraChairman & CEOTel: +41 22 594 3000info@sealsq.com SEALSQ Investor Relations (US)The Equity Group Inc.Lena CatiTel: +1 212 836-9611 lcati@theequitygroup.com The post SEALSQ Unveils SEALQuantum.com Innovation Lab Progress, Expanding into AI to Anticipate the Convergence with Quantum and Cybersecurity appeared first on ForexTV.

Collaboration Integrates Amaze’s E-Commerce Platform into Parler’s Social Media Ecosystem; Investment Underscores Confidence and Value in Amaze’s Creator-First Model NEWPORT BEACH, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Amaze Holdings, Inc. (NYSE American: AMZE) (“Amaze”) a global leader in creator-powered commerce, today announced a strategic partnership with Parler Cloud Technologies (“Parler”), the parent company of Pulse, and an above-market investment by Parler to purchase common stock and warrants of Amaze. The exclusive partnership will integrate Amaze’s e-commerce platform into Parler’s social media properties, including PlayTV and Parler.com. The integration will enable creators to sell products directly through Parler’s growing network, furthering Amaze’s mission to power creator monetization at scale. The investment is pursuant to a securities purchase agreement under which Parler has agreed to buy one million shares of Amaze common stock at $6 per share, a premium to Amaze’s current share price, and three-year warrants to purchase up to an additional one million Amaze shares at $7.50 per share. This amounts to a $6 million current investment and up to $7.5 million additional investment upon exercise of the warrants. “At Amaze, we are committed to being the first-party commerce engine for creators worldwide,” said Aaron Day, Chairman and CEO of Amaze Holdings, Inc. “We believe that this strategic partnership and investment by Parler is proof positive of the progress Amaze has made to date as being a best-in-class solution. Parler’s platforms are gaining traction globally, championing creators of all backgrounds, creator-first monetization and modern technology. Together, our companies can deliver powerful tools such as next-generation cloud services, payment services and connectivity across all social media’s global needs. This unlocks new opportunities for creators to build sustainable businesses.” Day added, “This partnership aligns with a broader industry shift toward the convergence of social media, social commerce and modern payment solutions. Most social media platforms were built 10-20 years ago and there is a need for a modern commerce stack to keep pace with the needs of creators and fans. By integrating with Parler, we’re giving creators a platform built on cutting-edge infrastructure, transparency and global commerce capabilities. We believe our platform and engine will serve as a major contributor to value creation for our clients, and ultimately all of our shareholders.” The integration is expected to roll out by the end of the year, with Amaze serving as Parler’s primary e-commerce partner. The closing of the investment by Parler is subject to customary due diligence within 60 days or less. For investor information, please contact IR@amaze.co For press inquiries, please contact PR@amaze.co About Amaze:Amaze Software, Inc. is an end-to-end, creator-powered commerce platform offering tools for seamless product creation, advanced e-commerce solutions, and scalable managed services. By empowering anyone to “sell anything, anywhere,” Amaze enables creators to tell their stories, cultivate deeper audience connections, and generate sustainable income through shoppable, authentic experiences. Discover more at www.amaze.co. About Parler Cloud Technologies:Parler Cloud Technologies is a next-generation cloud infrastructure provider specializing in private cloud hosting, CDN services, and blockchain-powered digital ecosystems. As an Open Compute Project (OCP) Solution Provider, Parler Cloud delivers Infrastructure-as-a-Service (IaaS) solutions designed for performance, security, and decentralization. Its infrastructure powers the Parler ecosystem and third-party businesses, ensuring high-performance content delivery and secure cloud hosting. Cautionary Note Regarding Forward-Looking StatementsThis press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). These statements relate to future events and developments or to our future operating or financial performance, are subject to risks and uncertainties and are based estimates and assumptions. Forward-looking statements may include, but are not limited to, statements about our strategies, partnerships, initiatives, growth, investments, revenues, expenditures, the size of our market, our plans and objectives for future operations, and future financial and business performance. These statements can be identified by words such as such as “may,” “might,” “should,” “would,” “could,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “potential” or “continue,” and are based our current expectations and views concerning future events and developments and their potential effects on us. These statements are subject to known and unknown risks, uncertainties and assumptions that could cause actual results to differ materially from those projected or otherwise implied by the forward-looking statement. These risks include: our ability to execute our plans and strategies; our limited operating history and history of losses; our financial position and need for additional capital; our ability to attract and retain our creator base and expand the range of products available for sale; we may experience difficulties in managing our growth and expenses; we may not keep pace with technological advances; there may be undetected errors or defects in our software or issues related to data computing, processing or storage; our reliance on third parties to provide key services for our business, including cloud hosting, marketing platforms, payment providers and network providers; failure to maintain or enhance our brand; our ability to protect our intellectual property; significant interruptions, delays or outages in services from our platform; significant data breach or disruption of the information technology systems or networks and cyberattacks; risks associated with international operations; general economic and competitive factors affecting our business generally; changes in laws and regulations, including those related to privacy, online liability, consumer protection, and financial services; our dependence on senior management and other key personnel; and our ability to attract, retain and motivate qualified personnel and senior management. Additional risks and uncertainties that could cause actual outcomes and results to differ materially from those contemplated by the forward-looking statements are included in our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and other future filings and reports that we file with the Securities and Exchange Commission (SEC) from time to time. Given these risks and uncertainties, you should not place undue reliance on these forward-looking statements. Also, these forward-looking statements represent our estimates and assumptions only as of the date of the press release. Unless required by law, we undertake no obligation to update or revise any forward-looking statements to reflect new information or future events or developments. The post Amaze Forms Strategic Partnership with Parler Cloud Technologies, the Parent Company of Pulse, and Announces $6 Million Above-Market Investment by Parler appeared first on ForexTV.

Austin, Texas, Aug. 11, 2025 (GLOBE NEWSWIRE) -- via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the launch of DefenseWireNews (“DWN”) as part of its sustained effort to provide specialized content distribution via widespread syndication channels. DefenseWireNews is a specialized communications platform covering developments and innovations across the defense, aerospace, and cybersecurity sectors. DWN delivers news, analysis, and company spotlights highlighting mission-critical technologies and the public companies driving them forward. Alongside original editorial coverage, DefenseWireNews issues time-sensitive updates through investor-focused text alerts and social media notifications. The platform keeps its audience informed on contract awards, procurement trends, geopolitical shifts, and the strategic moves of companies operating where public markets meet national security demand. From industry giants like Lockheed Martin Corp., RTX Corp., and Northrop Grumman Corp. to emerging public innovators advancing next-generation platforms, DWN offers a comprehensive view of the companies shaping the future of defense. The platform helps investors track high-growth firms strategically positioned to benefit from expanding budgets and evolving global priorities. The launch of DefenseWireNews reinforces IBN’s commitment to the continued expansion of its Dynamic Brand Portfolio, followers, and products. For more than 19 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate communications solutions to 600+ public and private companies. To learn more about IBN’s achievements and milestones, our visual timeline www.IBN.fm/TimeLine About IBN IBN consists of financial brands introduced to the investment public over the course of 19+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients. Through our Dynamic Brand Portfolio (DBP), IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) Press Release Enhancement to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) total news coverage solutions. For more information, please visit https://www.InvestorBrandNetwork.com Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer Forward-Looking Statements This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company's SEC filings. These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements. Corporate Communications IBN Austin, Texas www.InvestorBrandNetwork.com 512.354.7000 Office Editor@InvestorBrandNetwork.com The post IBN Launches DefenseWireNews to Spotlight Innovators in Defense, Aerospace, and Cybersecurity appeared first on ForexTV.

COPENHAGEN, Denmark, August 11, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will provide a business update and report its second quarter 2025 financial results on Thursday August 14, 2025, before opening of the Nasdaq CM. Evaxion’s Executive Management will host a conference call and webcast the same day at 14:30 CET/08:30 EST, presenting the update and results as well as taking questions. This event is free, open to the public and encouraged. To join the conference call, listen to the presentation and ask verbal questions, please register in advance via this link to receive the dial-in telephone numbers and a unique PIN code. The call can be accessed 15 minutes prior to the start of the live event. To join the webcast, please click on this link. The webcast recording will be available on our website shortly after the event. Contact information Evaxion A/SMads KronborgVice President, Investor Relations & Communication+45 53 54 82 96mak@evaxion.ai  About EVAXION Evaxion A/S is a pioneering TechBio company based upon its AI platform, AI-Immunology™. Evaxion’s proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Based upon AI-Immunology™, Evaxion has developed a clinical-stage oncology pipeline of novel personalized vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. Evaxion is committed to transforming patients’ lives by providing innovative and targeted treatment options. For more information about Evaxion and its groundbreaking AI-Immunology™ platform and vaccine pipeline, please visit our website. Forward-looking statement This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words “target,” “believe,” “expect,” “hope,” “aim,” “intend,” “may,” “might,” “anticipate,” “contemplate,” “continue,” “estimate,” “plan,” “potential,” “predict,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could,” and other words and terms of similar meaning identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including, but not limited to, risks related to: our financial condition and need for additional capital; our development work; cost and success of our product development activities and preclinical and clinical trials; commercializing any approved pharmaceutical product developed using our AI platform technology, including the rate and degree of market acceptance of our product candidates; our dependence on third parties including for conduct of clinical testing and product manufacture; our inability to enter into partnerships; government regulation; protection of our intellectual property rights; employee matters and managing growth; our ADSs and ordinary shares, the impact of international economic, political, legal, compliance, social and business factors, including inflation, and the effects on our business from other significant geopolitical and macro-economic events; and other uncertainties affecting our business operations and financial condition. For a further discussion of these risks, please refer to the risk factors included in our most recent Annual Report on Form 20-F and other filings with the US Securities and Exchange Commission (SEC), which are available at www.sec.gov. We do not assume any obligation to update any forward-looking statements except as required by law.  The post Evaxion to announce business update and second quarter 2025 financial results on August 14, 2025 appeared first on ForexTV.

- Released positive topline data from the VIRAGE Phase 2b study of VCN-01 (zabilugene almadenorepvec); expanded data to be presented at the European Society for Medical Oncology (ESMO) 2025 Congress in October - - VCN-01 demonstrates potential in retinoblastoma with Phase 1 safety and clinical outcome data presented at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting - - Cash and cash equivalents of $12.1 million as of June 30, 2025, expected cash runway into Q1 2026 - ROCKVILLE, Md., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today reported financial results for the second quarter ended June 30, 2025, and provided a corporate update. “We are highly encouraged by the progress we’ve made so far in the first half of 2025,” said Steven A. Shallcross, Chief Executive Officer of Theriva Biologics. “We have achieved a significant milestone with the positive readout from the Phase 2b VIRAGE trial, where our lead asset VCN-01 (zabilugene almadenorepvec) achieved its primary survival and safety endpoints in metastatic pancreatic cancer patients treated with first-line standard of care chemotherapy gemcitabine/nab-paclitaxel. We are now preparing a study protocol for a potential Phase 3 clinical trial and advancing VCN-01’s manufacturing scale-up using our propietary suspension cell line. Leveraging our clinical and manufacturing momentum, we have also initiated strategic outreach to identify potential partners for VCN-01’s late-stage clinical development.” Recent Highlights and Anticipated Milestones VCN-01 Metastatic Pancreatic Ductal Adenocarcinoma (PDAC): Positive topline results from the VIRAGE Phase 2b trial were announced in May. PDAC patients treated with VCN-01 (zabilugene almadenorepvec) plus gemcitabine/nab-paclitaxel standard-of-care (SoC) chemotherapy had increased overall survival (OS), progression free survival (PFS), and duration of response (DOR) compared to patients treated with gemcitabine/nab-paclitaxel SoC. Theriva hosted a virtual event featuring eminent pancreatic cancer clinician/researchers to review and discuss the data from the VIRAGE trial of VCN-01. To access the replay of the event, click HERE. Theriva and VIRAGE trial investigators participated in an off-site meeting during the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting to review the topline data and discuss the conclusions relevant to the design and execution of a potential Phase 3 clinical trial in metastatic pancreatic ductal adenocarcinoma (PDAC). Expanded data from the VIRAGE trial are to be presented at a mini oral session at the European Society for Medical Oncology (ESMO) 2025 Congress. The presentation entitled “VIRAGE trial: randomized Phase IIb, open-label, study of Nab-Paclitaxel and Gemcitabine with/without intravenous VCN-01 in Patients with Metastatic Pancreatic Cancer (mPDAC)” (abstract 2216MO) is planned to be presented on Monday, October 20, 2025 by Dr. Rocío García-Carbonero, Hospital 12 de Octubre, Madrid, Spain and subsequently reviewed by an invited Discussant. Retinoblastoma: As previously announced, safety and clinical outcomes of Phase 1 study (NCT03284268) of VCN-01 (zabilugene almadenorepvec) in refractory retinoblastoma patients were presented during a poster session at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois on Saturday, May 31, 2025. The abstract can be viewed here. Second Quarter Ended June 30, 2025 Financial Results General and administrative expenses increased to $11.2 million for the three months ended June 30, 2025, from $1.5 million for the three months ended June 30, 2024. This increase of 662% is primarily comprised of the increase in fair value of the contingent consideration adjustment of $9.2 million due to the VIRAGE Phase 2b clinical trial of VCN-01 in PDAC achieving its primary endpoint and increased registration fees. The charge related to stock-based compensation expense was $97,000 for the three months ended June 30, 2025, compared to $114,000 for the three months ended June 30, 2024. Research and development expenses decreased to $2.0 million for the three months ended June 30, 2025, from approximately $3.0 million for the three months ended June 30, 2024. This decrease of 34% is primarily the result of lower clinical trial expenses related to the Company’s VIRAGE Phase 2b clinical trial of VCN-01 in PDAC, lower indirect cost related to decreased VCN-01 manufacturing costs and lower clinical trial expenses related to its Phase 1b/2a clinical trial of SYN-004 (ribaxamase) in allogeneic HCT recipients, offset by higher patent expenses related to SYN-020. Theriva anticipates research and development expense to increase as it completes its VIRAGE Phase 2b clinical trial of VCN-01 and plans for its potential Phase 3 clinical trial of VCN-01 in PDAC, advances its VCN-01 program in retinoblastoma, expands GMP scale-up manufacturing activities for VCN-01, and continues supporting the Company’s other preclinical and discovery initiatives. The charge related to stock-based compensation expense was $76,000 for the three months ended June 30, 2025, compared to $58,000 related to stock-based compensation expense for the three months ended June 30, 2024. Other income was $74,000 for the three months ended June 30, 2025 compared to other income of $172,000 for the three months ended June 30, 2024. Other income for the three months ended June 30, 2025 is primarily comprised of interest income of $54,000 and an exchange gain of $20,000. Other income for the three months ended June 30, 2024 is primarily comprised of interest income of $173,000 and exchange loss of $1,000. Cash and cash equivalents totaled $12.1 million as of June 30, 2025, compared to $11.6 million as of December 31, 2024. The Company expects that its cash position of $9.5 million as of early August 2025, will be able to fund its operations into the first quarter of 2026. About VCN-01 VCN-01 (zabilugene almadenorepvec) is a systemically administered oncolytic adenovirus designed to selectively and aggressively replicate within tumor cells and degrade the tumor stroma that serves as a significant physical and immunosuppressive barrier to cancer treatment. This unique mode-of-action enables VCN-01 to exert multiple antitumor effects by (i) selectively infecting and lysing tumor cells; (ii) enhancing the access and perfusion of co-administered chemotherapy products; and (iii) increasing tumor immunogenicity and exposing the tumor to the patient’s immune system and co-administered immunotherapy products. Systemic administration enables VCN-01 to exert its actions on both the primary tumor and metastases. VCN-01 has been administered to 142 patients to date in clinical trials of different cancers, including PDAC (in combination with chemotherapy), head and neck squamous cell carcinoma (with an immune checkpoint inhibitor), ovarian cancer (with CAR-T cell therapy), colorectal cancer, and retinoblastoma (by intravitreal injection). More information on these clinical trials is available at Clinicaltrials.gov. About Pancreatic Ductal Adenocarcinoma Cancer of the pancreas consists of two main histological types: cancer that arises from the ductal (exocrine) cells of the pancreas or, much less often, cancers may arise from the endocrine compartment of the pancreas. Pancreatic ductal adenocarcinoma (“PDAC”) accounts for more than 90% of all pancreatic tumors. It can be located either in the head of the pancreas or in the body/tail. Pancreatic cancer usually metastasizes to the liver and peritoneum. Other less common metastatic sites are the lungs, brain, kidney and bone. In its early stages, pancreatic cancer does not typically result in any characteristic symptoms, so in most cases it is diagnosed in its late stages (locally advanced non-metastatic or metastatic disease) when surgical resection and possibly curative treatment is not possible. It is generally assumed that only 10% of cases are resectable at presentation, whereas 30-40% of patients are diagnosed at local advanced/unresectable stage and 50-60% present with distant metastases. About VIRAGE VIRAGE was a two-arm, Phase 2b open-label, randomized, controlled, multicenter clinical trial in patients with histologically confirmed, newly-diagnosed metastatic PDAC. Patients were enrolled at 5 sites in the U.S. and 9 sites in Spain. In both the control and VCN-01 (zabilugene almadenorepvec) treatment arms, patients received gemcitabine/nab-paclitaxel standard-of-care chemotherapy in repeated 28-day cycles until disease progression. In the VCN-01 treatment arm only, patients were also administered intravenous VCN-01 seven-days prior to starting the first and fourth cycles of gemcitabine/nab-paclitaxel treatment (study days 1 and ~92 respectively). Primary endpoints for the trial include overall survival and VCN-01 safety/tolerability. Additional endpoints include progression free survival, duration of response, and measures of VCN-01 biodistribution, replication, and immune response. More information about the trial is available on Clinicaltrials.gov (NCT05673811), through the Spanish Clinical Trials Registry and European Union Drug Regulating Authorities Clinical Trials Database (EudraCT Number: 2022-000897-24). About Retinoblastoma Retinoblastoma is a tumor that originates in the retina and is the most common type of eye cancer in children. It occurs in approximately 1/14,000 – 1/18,000 live newborns and accounts for 15% of the tumors in the pediatric population < 1 year old. The average age of pediatric patients at diagnosis is 2, and it rarely occurs in children older than 6. In Europe, retinoblastoma has an estimated incidence rate of 1 per 13,844 live births (14.1 per million children under the age of 5) with approximately 300 children diagnosed per year (Stacey et al. 2021). Preserving life and preventing the loss of an eye, blindness, and other serious effects of treatment that reduce the patient’s life span or the quality of life remains a challenge. In addition, children with retinoblastoma have been more likely to lose their eye and die of metastatic disease in low-resource countries. About Theriva™ Biologics, Inc. Theriva™ Biologics (NYSE American: TOVX), is a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need. The Company is advancing a new oncolytic adenovirus platform designed for intravenous (IV), intravitreal and antitumoral delivery to trigger tumor cell death, improve access of co-administered cancer therapies to the tumor, and promote a robust and sustained anti-tumor response by the patient’s immune system. The Company’s lead candidates are: (1) VCN-01, an oncolytic adenovirus designed to replicate selectively and aggressively within tumor cells, and to degrade the tumor stroma barrier that serves as a significant physical and immunosuppressive barrier to cancer treatment; (2) SYN-004 (ribaxamase) which is designed to degrade certain commonly used IV beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent microbiome damage, thereby limiting overgrowth of pathogenic organisms such as VRE (vancomycin resistant Enterococci) and reducing the incidence and severity of acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT) recipients; and (3) SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) produced under cGMP conditions and intended to treat both local GI and systemic diseases. For more information, please visit Theriva Biologics’ website at www.therivabio.com.   Forward-Looking Statement This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases forward-looking statements can be identified by terminology such as “may,” “should,” “potential,” “continue,” “expects,” “anticipates,” “intends,” “plans,” “believes,” “estimates,” and similar expressions. These forward-looking statements are based on management’s expectations and assumptions as of the date of this press release and are subject to a number of risks and uncertainties, many of which are difficult to predict that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding expanded data from the VIRAGE Phase 2b study of VCN-01 being presented at the ESMO 2025 Congress in October; the potential of VCN-01 to treat retinoblastoma; having a cash runway into the first quarter of 2026; preparing a study protocol for a potential Phase 3 clinical trial and advancing VCN-01’s manufacturing scale-up using the Company’s propietary suspension cell line; research and development expenses increasing as the Company completes its VIRAGE Phase 2b clinical trial of VCN-01 and plans for its potential Phase 3 clinical trial of VCN-01 in PDAC, advances its VCN-01 program in retinoblastoma, expands GMP scale-up manufacturing activities for VCN-01, and continues supporting the Company’s other preclinical and discovery initiatives. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except as required under applicable law. Important factors that could cause actual results to differ materially from those in the forward-looking statements include the ability of VCN-01 to have therapeutic benefits and continue to do so in future trials; the Company having a cash runway being able to support its operations into the first quarter of 2026, including expected increases in research and development expenses, and the risk factors that are described in the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and other documents filed by the Company from time to time with the SEC, including the Company’s subsequent Quarterly Reports on Form 10-Q filed with the SEC that are incorporated by reference therein. The Company does not undertake or accept any obligation to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based. For further information, please contact:Investor RelationsKevin GardnerLifeSci Advisors, LLC kgardner@lifesciadvisors.com   Condensed Consolidated Balance Sheets (In thousands except share and par value amounts)               June 30, 2025   December 31, 2024 Assets                       Current Assets           Cash and cash equivalents $ 12,120     $ 11,609   Tax credit receivable   1,722       3,228   Prepaid expenses and other current assets   901       1,444   Total Current Assets   14,743       16,281               Non-Current Assets           Property and equipment, net   258       270   Restricted cash   46       96   Right of use asset   1,077       1,272   In-process research and development   19,624       17,358   Deposits and other assets   82       75   Total Assets $ 35,830     $ 35,352               Liabilities and Stockholders’ Equity                       Current Liabilities:           Accounts payable $ 607     $ 859   Accrued expenses   9,017       3,368   Accrued employee benefits   759       1,144   Deferred research and development tax credit-current portion   1,343       1,614   Loans payable-current   56       61   Operating lease liability-current portion   612       539   Total Current Liabilities   12,394       7,585               Non-current Liabilities           Non-current contingent consideration   10,160       6,973   Loan Payable - non-current   1,639       92   Non-current deferred research and development tax credit   430       762   Non-current operating lease liability   584       873   Total Liabilities   25,207       16,285               Commitments and Contingencies (Note 13)           Stockholders’ Equity:           Preferred Stock; 10,000,000 authorized; none issued or outstanding at June 30, 2025 and December 31, 2024   —       —   Common stock, $0.001 par value; 350,000,000 shares authorized, 9,088,042 issued and 9,059,232 outstanding at June 30, 2025 and 2,811,259 issued and 2,782,449 outstanding at December 31, 2024   8       3   Additional paid-in capital   362,463       355,501   Treasury stock at cost, 28,809 shares at June 30, 2025 and at December 31, 2024   (288 )     (288 ) Accumulated other comprehensive income (loss)   793       (1,178 ) Accumulated deficit   (352,353 )     (334,971 ) Total Stockholders’ Equity   10,623       19,067               Total Liabilities and Stockholders’ Equity $ 35,830     $ 35,352                   Condensed Consolidated Statements of Operations and Comprehensive Loss (In thousands, except share and per share amounts) (Unaudited)                             For the three months ended June 30,   For the six months ended June 30,   2025   2024   2025   2024 Operating Costs and Expenses:                       General and administrative   11,179       1,467       12,628       3,401   Research and development   1,953       2,953       4,921       6,412   Goodwill impairment   —       4,068       —       4,068   Total Operating Costs and Expenses   13,132       8,488       17,549       13,881                           Loss from Operations   (13,132 )     (8,488 )     (17,549 )     (13,881 )                         Other Income/Expense:                       Foreign currency exchange (loss) gain   20       (1 )     17       (2 ) Interest income, net   54       173       150       402   Total Other Income   74       172       167       400                           Net Loss   (13,058 )     (8,316 )     (17,382 )     (13,481 ) Income tax benefit   —       —       —       —   Net Loss Attributable to Common Stockholders $ (13,058 )   $ (8,316 )   $ (17,382 )   $ (13,481 )                         Net Loss Per Share - Basic and Dilutive $ (1.93 )   $ (10.72 )   $ (3.64 )   $ (18.45 )                         Weighted average number of shares outstanding during the period - Basic and Dilutive   6,752,953       775,736       4,778,669       730,826                           Net Loss   (13,058 )     (8,316 )     (17,382 )     (13,481 ) Gain (loss) on foreign currency translation   1,317       (172 )     1,971       (741 ) Total comprehensive loss $ (11,741 )   $ (8,488 )   $ (15,411 )   $ (14,222 ) The post Theriva™ Biologics Reports Second Quarter 2025 Operational Highlights and Financial Results appeared first on ForexTV.

4D-150 Phase 3 program in wet AMD advancing ahead of plan, with expected 4FRONT-1 data readout accelerated to H1 2027 from H2 2027 and 4FRONT-2 initiated ahead of schedule Presented positive 60-week results from 4D-150 SPECTRA clinical trial in DME Streamlined organization to drive late-stage execution $417 million in cash, cash equivalents and marketable securities as of June 30, 2025, expected to fund planned operations into 2028  EMERYVILLE, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today reported Q2 2025 financial results, provided operational highlights and outlined expected upcoming milestones.  “During the past quarter, we advanced our 4D-150 program and streamlined operations to focus on late-stage execution,” said David Kirn, M.D., Co-founder and Chief Executive Officer of 4DMT. “Rapid enrollment in 4FRONT-1 has enabled us to accelerate the topline data expectation to the first half of 2027, and we initiated 4FRONT-2 ahead of schedule. These updates reflect strong team execution and continued enthusiasm from investigators and patients for 4D-150 as a potential genetic medicine backbone therapy in wet AMD. We also aligned our organization around key priorities for 4D-150 in wet AMD: completing Phase 3, filing a BLA and preparing for potential commercialization. In parallel, we reported positive 60-week data from the SPECTRA trial in DME, which continues to support favorable tolerability, sustained durability and meaningful treatment burden reduction. We are pleased to now be aligned with both the FDA and the European Medicines Agency (EMA) that a single successful Phase 3 study could support approval in the U.S. and Europe.” Recent Corporate Highlights Streamlined Organization to Drive Accelerated Phase 3 Development  Announced a workforce reduction of approximately 25% of current and planned roles in July 2025, primarily in the areas supporting early-stage research and development and support functions  The workforce reduction is expected to provide annual cash compensation cost savings of approximately $15 million and offsets additional expenses expected based on the accelerated timelines for the 4FRONT clinical trials and Biologics License Application (BLA) preparation, which supports the Company’s cash runway into 2028, as previously guided Recent Highlights and Expected Milestones for 4D-150 4D-150 for Wet Age-related Macular Degeneration (Wet AMD):  4FRONT Global Phase 3 Program: Initial enrollment and site activation for 4FRONT-1, the North American Phase 3 clinical trial of 4D-150 in wet AMD, have exceeded initial projections, reflecting continued strong engagement and enthusiasm from investigators and patients 52-week topline data expected in H1 2027, accelerated from previous guidance of H2 2027 The second Phase 3 trial of 4D-150 in wet AMD, 4FRONT-2, was initiated in June 2025, ahead of schedule 52-week topline data for 4FRONT-2 are expected in H2 2027  PRISM Phase 1/2 Clinical Trial: 2-year data from Phase 1/2a and 18-month data from Phase 2b cohorts expected in Q4 2025   4D-150 for Diabetic Macular Edema (DME): SPECTRA Clinical Trial:  Presented positive 60-week results (data cutoff: May 3, 2025)     Across all patients and dose levels treated to date, 4D-150 continues to be well tolerated, with no intraocular inflammation observed at any timepoint or dose level No subjects required modification to the topical corticosteroid regimen, and all patients are currently off corticosteroids No hypotony, endophthalmitis, vasculitis, choroidal effusions or retinal artery occlusions were reported Mean intraocular pressure was within normal limits   Post-three loading doses of aflibercept, 3E10 vg/eye, the Phase 3 dose demonstrated strong signals of clinical activity, with sustained gain of BCVA of +9.7 letters and reduction of CST of -174 µm from baseline Supplemental injections: Utilized stringent supplemental aflibercept criteria to maximize patient safety while assessing initial clinical activity Clear dose response observed for the Phase 3 dose vs. lower doses (58% fewer injections) Phase 3 dose achieved 78% reduction in injection burden vs. projected on-label aflibercept 2mg Q8W Phase 3 Planning: Following U.S. Food and Drug Administration (FDA) alignment, as communicated in January 2025, EMA is also aligned that a single Phase 3 clinical trial, based on data generated to date for 4D-150 in both the SPECTRA and PRISM clinical trials combined with data from the two ongoing wet AMD Phase 3 clinical trials, would be acceptable as the basis for a marketing authorization application submission for 4D-150 in DME Received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for 4D-150 for the treatment of DME Next steps pending final FDA and EMA alignment on Phase 3 clinical trial design and funding pathway Recent Highlights and Expected Milestones in Pulmonology Program 4D-710 for Cystic Fibrosis Lung Disease:  Completed enrollment of Cohort 4 (n=6) in Phase 1 stage of AEROW clinical trial (completed total enrollment of n=16 participants) Interim data from AEROW clinical trial and program update expected in Q4 2025  Q2 2025 Financial Results Cash Position: Cash, cash equivalents and marketable securities were $417 million as of June 30, 2025, as compared to $505 million as of December 31, 2024. The net decrease in cash was primarily a result of cash used in operations. We currently expect cash, cash equivalents and marketable securities to be sufficient to fund planned operations into 2028. R&D Expenses: Research and development expenses were $48.0 million for the second quarter of 2025, as compared to $31.9 million for the second quarter of 2024. This increase was primarily driven by the initiation of our first Phase 3 clinical trial of 4D-150 in wet AMD, including increased personnel and professional services to support Phase 3 development. G&A Expenses: General and administrative expenses were $11.5 million for the second quarter of 2025, as compared to $10.6 million for the second quarter of 2024. This increase was primarily driven by increased use of professional services. Net Loss: Net loss was $54.7 million for the second quarter of 2025, as compared to net loss of $35.0 million for the second quarter of 2024. About 4DMT   4DMT is a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. The Company’s lead product candidate 4D-150 is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) with a single, safe, intravitreal injection, which substantially reduces the treatment burden associated with current bolus injections. The Company’s lead indication for 4D-150 is wet age-related macular degeneration, which is currently in Phase 3 development, and second indication is diabetic macular edema. The Company’s second product candidate is 4D-710, which is the first known genetic medicine to demonstrate successful delivery and expression of the CFTR transgene in the lungs of people with cystic fibrosis after aerosol delivery. 4D Molecular Therapeutics™, 4DMT™, Therapeutic Vector Evolution™, and the 4DMT logo are trademarks of 4DMT.   All of the Company’s product candidates are in clinical or preclinical development and have not yet been approved for marketing by the U.S. Food and Drug Administration or any other regulatory authority. No representation is made as to the safety or effectiveness of the Company’s product candidates for the therapeutic uses for which they are being studied.  Learn more at www.4DMT.com and follow us on LinkedIn.  Forward-Looking Statements: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements regarding the therapeutic potential and clinical benefits of, as well as the plans, announcements and related timing for the clinical development of our product candidates and interactions with FDA and statements regarding our financial performance, results of operations and anticipated cash runway. The words "may," “might,” "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," “expect,” "estimate," “seek,” "predict," “future,” "project," "potential," "continue," "target" and similar words or expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including risks and uncertainties that are described in greater detail in the section entitled "Risk Factors" in 4D Molecular Therapeutics’ most recent Quarterly Report on Form 10-Q to be filed on or about the date hereof, as well as any subsequent filings with the Securities and Exchange Commission. In addition, any forward-looking statements represent 4D Molecular Therapeutics' views only as of today and should not be relied upon as representing its views as of any subsequent date. 4D Molecular Therapeutics explicitly disclaims any obligation to update any forward-looking statements. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. 4D Molecular Therapeutics, Inc.Statements of Operations (Unaudited)(in thousands, except share and per share amounts)           Three months ended June 30,     Six months ended June 30,       2025     2024     2025     2024   Revenue:                         Collaboration and license revenue   $ 15     $ 5     $ 29     $ 33   Operating expenses:                         Research and development     47,951       31,860       88,650       59,727   General and administrative     11,519       10,601       24,456       20,898   Total operating expenses     59,470       42,461       113,106       80,625   Loss from operations     (59,455 )     (42,456 )     (113,077 )     (80,592 ) Other income, net     4,797       7,503       10,447       13,238   Net loss   $ (54,658 )   $ (34,953 )   $ (102,630 )   $ (67,354 ) Net loss per share, basic and diluted   $ (0.98 )   $ (0.63 )   $ (1.84 )   $ (1.29 ) Weighted-average shares outstanding used in computing net loss per share, basic and diluted     55,927,091       55,282,754       55,836,075       52,277,369   4D Molecular Therapeutics, Inc.Balance Sheet Data(Unaudited)(in thousands)           June 30,     December 31,       2025     2024   Cash, cash equivalents and marketable securities   $ 417,031     $ 505,460   Total assets     473,637       560,384   Total liabilities     52,747       49,778   Accumulated deficit     (678,825 )     (576,195 ) Total stockholders’ equity     420,890       510,606   Contacts: Media: Jenn Gordon dna Communications Media@4DMT.com  Investors: Julian PeiHead of Investor Relations and Strategic FinanceInvestor.Relations@4DMT.com  The post 4DMT Reports Second Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones appeared first on ForexTV.

The GBP/USD weekly forecast shows a drop in BoE rate cut expectations. Nearly half of the BoE officials were ready to keep interest rates unchanged. US unemployment claims data further supported rate cut bets. The GBP/USD weekly forecast shows a drop in BoE rate cut expectations after a divided vote at the last meeting. Ups… […] The post GBP/USD Weekly Forecast: Odds for Near-Term Rate Cut Lowered appeared first on ForexTV.

The AUD/USD weekly forecast points to a likely RBA rate cut on Tuesday. Markets interpreted Trump’s Fed replacement as dovish. US unemployment claims rose, fueling concerns about the labor market.  The AUD/USD weekly forecast points to a likely RBA rate cut on Tuesday that could drag the Australian dollar lower. Ups and downs of AUD/USD … […] The post AUDUSD Weekly Forecast: RBA Poised for a Rate Cut appeared first on ForexTV.

Delray Beach, FL, Aug. 10, 2025 (GLOBE NEWSWIRE) -- The report "GPU as a Service Market by Service Model (IaaS, PaaS), GPU Type (High-end GPUs, Mid-range GPUs, Low-end GPUs), Deployment (Public Cloud, Private Cloud, Hybrid Cloud), Enterprise Type (Large Enterprises, SMEs) - Global Forecast to 2030" The GPU as a Service market is expected to grow from USD  8.21 billion in 2025 and is estimated to reach USD 26.62 billion by 2030; it is expected to grow at a Compound Annual Growth Rate (CAGR) of 26.5% from 2025 to 2030. The surge in AI and machine learning applications is a primary driver for the GPU as a Service (GPUaaS) market. Industries such as healthcare, finance, and automotive require high-performance computing for tasks like data analysis, image recognition, and autonomous driving.   Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=153834402 Major Key Players in the GPU as a Service Industry: Amazon web Servies, Inc. (US), Microsoft (US), Google (US), Oracle (US), IBM (US), Coreweave (US), Alibaba Cloud (China), Lambda (US), Tencent Cloud (China), Jarvislabs.ai (India), among others. GPU as a Service Market Segmentation: By deployment, hybrid cloud segment is projected to grow at a high CAGR during the forecast period. Hybrid cloud deployment in the GPU as a Service (GPUaaS) market will grow at a high CAGR in the forecast period because of its ability to balance data security, cost-effectiveness and flexibility. Hybrid cloud models are being adopted increasingly by businesses to take advantage of both on-premises infrastructure and public cloud resources. This solution is especially helpful for AI inference and training workloads that demand scalable GPU capabilities without compromising data privacy. Financial institutions and healthcare organizations, for example, leverage hybrid cloud deployments to process sensitive data locally while utilizing cloud GPUs for training AI models. Companies such as NVIDIA offers DGX Cloud and AI Enterprise, enabling seamless deployment of AI across hybrid environments. By enterprise type- small and medium-sized enterprises (SMEs) segment will account for the high CAGR in 2025-2030. The small and medium-sized enterprises (SMEs) segment in the GPU as a Service  (GPUaaS) market is anticipated to grow at a high CAGR during the forecast period, driven by the increasing adoption of AI, machine learning (ML), and data analytics. SMEs often lack the capital to invest in expensive on-premises GPU infrastructure, making cloud-based GPUaaS a cost-efficient and scalable option. AWS, Azure, and Google Cloud provide SMEs with on-demand access to high-performance GPUs, which can be used to speed up AI model training, video rendering, and data analysis without having to make huge initial investments. GPUaaS supports pay-as-you-go pricing, which enables SMEs to efficiently manage operational costs. North America region will hold highest share in the GPU as a Service market. North America holds the maximum market share of the GPU as a Service market because of its strong technological infrastructure, advanced AI ecosystem, and presence of leading cloud service providers in the region. Amazon Web Services (AWS), Microsoft Azure and Google Cloud have headquarters in the region and provide scalable and reliable GPUaaS solutions. The adoption of artificial intelligence (AI) and machine learning (ML) among various industries like healthcare, finance, and gaming drives strong demand for GPU resources. Ask for Sample Report: https://www.marketsandmarkets.com/requestsampleNew.asp?id=153834402 GPU as Service Market Key Takeaway By 2025, the GPU as a Service market is projected to reach USD 8.81 billion, and is expected to grow to USD 26.62 billion by 2030, at a CAGR of approximately 26.5% By market dynamics, the growing need for parallel computing in AI, machine learning, deep learning, and data science applications is fueling the adoption of GPUaaS, offering scalable performance without infrastructure costs. By deployment model, the hybrid cloud segment is projected to grow at the highest CAGR during the forecast period, as enterprises seek to balance data control and cost-effective GPU scaling. By service model, the Infrastructure as a Service (IaaS) segment dominates the market due to its flexibility in providing GPU power to startups, research institutions, and enterprises on demand. By vertical, the media & entertainment segment is expected to witness significant adoption of GPUaaS, particularly for real-time rendering, video editing, game development, and animation. By regional market, North America is estimated to hold the largest market share due to the presence of major cloud service providers, early technology adoption, and robust AI research and deployment. By regional growth, the Asia Pacific region is expected to register the highest CAGR during the forecast period, driven by cloud computing growth, AI adoption, and increasing investments in GPU infrastructure. By competitive outlook, the market is moderately consolidated, with major players focusing on partnerships, product innovation, and cloud-based GPU infrastructure to maintain a competitive edge. CONTACT: About MarketsandMarkets™ MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook. Contact: Mr. Rohan Salgarkar MarketsandMarkets™ INC. 1615 South Congress Ave. Suite 103, Delray Beach, FL 33445, USA: +1-888-600-6441 Email: sales@marketsandmarkets.com Visit Our Website: www.marketsandmarkets.com The post GPU as a Service Market Set to Hit $26.62 Billion by 2030: What’s Driving the Growth? appeared first on ForexTV.